GOS-3 Cell Line

Product Name	GOS-3 Cell Line
Cat.No	RWT-808
Size	1*10^6 cells/vial
Description	GOS-3 Cell Line, originally described as a glioma cell line established from the tumor material of brain from a 55-year-old man with a mixed astro-oligodendroglioma (grade II/III); however, DNA fingerprinting at DSMZ showed clearly that this cell line is in reality a derivative of the human glioblastoma cell line U-343-MG; described in the literature to express neuroepithelial markers GFAP, vimentin and S-100 protein as well as pp60C-SRC, but not the neuro-specific variant pp60C-SRCN and to express neuropoietic factors CNTF, LIF and their receptors; LIF and oncostatin M induce growth inhibition and differentiation
Tissue	brain
Species	Homo sapiens, human
Gender	famale,55 years
Disease	mixed astro-oligodendroglioma
Biosafety Level	BSL 1. Runtogen determines the biosafety level of a material based on our risk assessment as guided by the current edition of Biosafety in Microbiological and Biomedical Laboratories (BMBL), U.S. Department of Health and Human Services.
Morphology	fibroblast-like Adherent
Culture Method	DMEM+10%FBS+4 mM L-glutamine
Quality Control	GOS-3 Cell Line is negative for mycoplasma, bacteria, yeast, and fungi.
Shipping	Cryopreserved cells are shipped with dry ice
Storage	Upon arrival, Check all containers for leakage or breakage. Remove the frozen cells from the dry ice packaging and immediately place the cells at a temperature below -130°C, preferably in liquid nitrogen vapor, until ready for use.
Warranty	GOS-3 Cell Line is warranted for 30 days from the date of shipment, provided that the customer has stored and handled the product according to the information included on the product datasheet, website, and COA.
Disclaimers	Our cell line product is intended for laboratory research use only. It is not intended for any human or animal therapeutic use, any animal or human consumption, or any diagnostic use. Any proposed commercial use is prohibited without a license from Runtogen.

Online Inquiry

Online Inquiry